Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 5/20 | 0.74 |
| ▸ | LMNA | P02545 | 5/20 | 0.74 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.72 |
| ▸ | MAPT | P10636 | 2/20 | 0.72 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.72 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.72 |
| ▸ | STS | P08842 | 2/20 | 0.70 |
| ▸ | ESR1 | P03372 | 5/20 | 0.68 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.68 |
| ▸ | PGR | P06401 | 2/20 | 0.68 |
| ▸ | AR | P10275 | 2/20 | 0.68 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.68 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.68 |
| ▸ | ATM | Q13315 | 2/20 | 0.68 |
| ▸ | ABCC1 | P33527 | 1/20 | 0.68 |
| ▸ | ABCC4 | O15439 | 1/20 | 0.68 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.68 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.68 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.68 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31508415 | 1.00 | HSD17B10 (0.74) | HSD17B10LMNAALDH1A1MAPTCYP2C9 | |
| SCHEMBL31508553 | 1.00 | HSD17B10 (0.74) | HSD17B10LMNAALDH1A1MAPTCYP2C9 | |
| SCHEMBL31508323 | 1.00 | HSD17B10 (0.74) | HSD17B10LMNAALDH1A1MAPTCYP2C9 | |
| SCHEMBL31508268 | 1.00 | HSD17B10 (0.74) | HSD17B10LMNAALDH1A1MAPTCYP2C9 | |
| SCHEMBL31508468 | 1.00 | HSD17B10 (0.74) | HSD17B10LMNAALDH1A1MAPTCYP2C9 | |
| SCHEMBL18541855 | 0.92 | HSD17B10 (0.77) | HSD17B10LMNAALDH1A1MAPTCYP2C9 | |
| SCHEMBL7533892 | 0.92 | HSD17B10 (0.77) | HSD17B10LMNAALDH1A1MAPTCYP2C9 | |
| SCHEMBL18487958 | 0.92 | HSD17B10 (0.77) | HSD17B10LMNAALDH1A1MAPTCYP2C9 | |
| SCHEMBL18687706 | 0.92 | HSD17B10 (0.77) | HSD17B10LMNAALDH1A1MAPTCYP2C9 | |
| SCHEMBL5438982 | 0.92 | HSD17B10 (0.77) | HSD17B10LMNAALDH1A1MAPTCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9708305-B2 | Substituted 1,2,3,4-tetrahydroisoquinoline derivatives for the treatment of hormone-dependent diseases | UNIVERSITé LAVAL (CA) | 2017-07-18 | — | — | US | disclosed |
| US-20160200685-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | UNIVERSITé LAVAL (CA) | 2016-07-14 | — | — | US | disclosed |
| WO-2015024111-A1 | COMPOUNDS FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | UNIVERSITE LAVAL (CA) | 2015-02-26 | — | — | WO | disclosed |
| US-8288367-B2 | Treatment or inhibition of a steroid hormone dependent disorder; reducing spermatogenesis or male virility; 17 beta -hydroxysteroid dehydrogenase (17 beta-HSD) inhibitors; compounds such as 3-(benzylamino)-15alpha-(4-morpholin-4-yl-4-oxobutyl)estra-1(10),2,4-trien-17-one | SOLVAY PHARMACEUTICALS GMBH (DE) | 2012-10-16 | — | — | US | disclosed |
| EP-2099814-A1 | SUBSTITUTED ESTRATRIEN DERIVATIVES AS 17BETA HSD INHIBITORS | Solvay Pharmaceuticals GmbH (DE) | 2009-09-16 | — | — | EP | disclosed |
| US-20080255075-A1 | SUBSTITUTED ESTRATRIENE DERIVATIVES AS 17BETA HSD INHIBITORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-10-16 | — | — | US | disclosed |
| WO-2008065100-A1 | SUBSTITUTED ESTRATRIEN DERIVATIVES AS 17BETA HSD INHIBITORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2008-06-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255075-A1 | SUBSTITUTED ESTRATRIENE DERIVATIVES AS 17BETA HSD INHIBITORS | HSD17B11, HSD17B1, HSD17B2 | HSD17B10 18/4885LMNA 3172/4885ALDH1A1 93/4885 |
| US-20160200685-A1 | SUBSTITUTED 1,2,3,4-TETRAHYDROISOQUINOLINE DERIVATIVES FOR THE TREATMENT OF HORMONE-DEPENDENT DISEASES | STS, SHBG, CYP19A1 | HSD17B10 178/4885LMNA 1221/4885ALDH1A1 1010/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.